A recent study reveals that individuals who come off new slimming jabs like Mounjaro or Wegovy may regain lost weight far faster than those who end conventional lifestyle programs.
Research printed in a major health publication demonstrates that while overweight people frequently drop substantial amounts of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such medications must be informed of the danger of quick rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to starting weight in about 18 months.
Weighing Approaches
The analysis, which examined dozens of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with other pills.
Scientists note that people who shed pounds through dieting generally experience a more gradual weight regain—around 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Nutrition scientists believe the mechanism of the drugs accounts for the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Disease?
Medical guidelines advise the injections for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals argue that, considering the high risk of relapse, the therapy might need to be long-term.
This opinion is echoed by drug manufacturers, who state that the findings "emphasize the long-term character of excess weight," similar to managing conditions like hypertension.
Patient Experiences
Individuals who have stopped the medication describe a sudden resurgence of hunger.
"It was like something that goes on and I was suddenly extremely hungry," described one woman.
This difficulty is exacerbated if users have not developed permanent dietary or behavioural modifications during therapy.
Significant Use
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a permanent fix and lasting health benefits likely depends on integrated lifestyle support.
